Even though previous studies in lean and HFD mice showed that of the classical TZDs, rosiglitazone has the most deleterious effect on bone loss in terms of inhibition of bone formation, increased osteoclastogenesis and induction of BMAT compared to pioglitazone [[45], [46], [47], [48], [49]], in our study we used pioglitazone in comparison to MSDC-0602K, as it is the only available PPARγ agonist used to treat T2D patients [[50], [51], [52]]. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.